Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

ESMO Guidelines Committee

doi:10.1016/j.annonc.2021.11.012

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ^☆

ESMO Guidelines Committee

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

285 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	244-258
Nombre de pages	15
journal	Annals of Oncology
Volume	33
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/j.annonc.2021.11.012
état	Publié - 1 mars 2022
Modification externe	Oui

Accès au document

10.1016/j.annonc.2021.11.012

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{64594c4be8534622a555665122ea42cd,

title = "Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆",

keywords = "antibody drug conjugates, bladder cancer, fibroblast growth factor receptor inhibitors, immune checkpoint inhibitors, platinum-based chemotherapy, urothelial carcinoma",

author = "{ESMO Guidelines Committee} and T. Powles and J. Bellmunt and E. Comperat and {De Santis}, M. and R. Huddart and Y. Loriot and A. Necchi and Valderrama, {B. P.} and A. Ravaud and Shariat, {S. F.} and B. Szabados and {van der Heijden}, {M. S.} and S. Gillessen",

year = "2022",

month = mar,

day = "1",

doi = "10.1016/j.annonc.2021.11.012",

language = "English",

volume = "33",

pages = "244--258",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "3",

}

TY - JOUR

T1 - Bladder cancer

T2 - ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

AU - ESMO Guidelines Committee

AU - Powles, T.

AU - Bellmunt, J.

AU - Comperat, E.

AU - De Santis, M.

AU - Huddart, R.

AU - Loriot, Y.

AU - Necchi, A.

AU - Valderrama, B. P.

AU - Ravaud, A.

AU - Shariat, S. F.

AU - Szabados, B.

AU - van der Heijden, M. S.

AU - Gillessen, S.

PY - 2022/3/1

Y1 - 2022/3/1

KW - antibody drug conjugates

KW - bladder cancer

KW - fibroblast growth factor receptor inhibitors

KW - immune checkpoint inhibitors

KW - platinum-based chemotherapy

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85123680300&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.11.012

DO - 10.1016/j.annonc.2021.11.012

M3 - Article

C2 - 34861372

AN - SCOPUS:85123680300

SN - 0923-7534

VL - 33

SP - 244

EP - 258

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -